Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
rare diseases
Biotech
At CNPV hearing, industry support meets ‘concern’ from experts
Comments at the June 4 public hearing largely fell along three main fault lines.
Darren Incorvaia
Jun 5, 2026 5:00am
Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit
Jun 1, 2026 8:31am
AstraZeneca, after phase 3 miss, posts data behind approval bid
May 29, 2026 10:15am
FDA extends Beren’s rare disease review after info request
May 28, 2026 10:45am
Relay ‘full steam ahead’ on PI3K drug after rare disease readout
May 19, 2026 6:00am
Sanofi, Wave post updates in race to end AATD’s 40-year drought
May 18, 2026 4:30pm
